ArticleJCEM case reports2025
Severe Hyperandrogenism Secondary to Polycystic Ovarian Syndrome in a Gender-diverse Adolescent.
Article in JCEM case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of gender identity takes place under the influence of a complex interplay of social, psychological, and biological factors. Studies in individuals with disorders of sex development have suggested that exposure to androgens during fetal development and across the lifespan may contribute to a more masculine gender identity. We describe here an individual designated female at birth who presented with severe hyperandrogenism (total testosterone 337 ng/dL, 11.7 nmol/L) (reference range, 6-50 ng/dL [0.21-1.74 nmol/L]) and virilization secondary to polycystic ovarian syndrome in the setting of gender identity exploration. On presentation the patient endorsed a masculine gender identity, and after GnRH analog therapy reduced total testosterone to the cisgender female range, endorsed a feminine gender identity. This case adds to what is known about the possible range of androgen excess in polycystic ovarian syndrome and demonstrates the diagnosis and treatment of polycystic ovarian syndrome in a gender diverse adolescent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.